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Dual antiplatelet therapy (DAPT) after percutaneous coronary intervention increases the risk of bleeding.We studied the safety and
clinical outcomes of switching fromDAPT to aspirinmonotherapy at 3months after ZES implantation.We retrospectively evaluated
168 consecutive patientswith coronary artery diseasewhohad been implantedwith aZES from June 2009 throughMarch 2010.After
excluding 40 patients according to exclusion criteria such as myocardial infarction, 128 patients were divided into a 3-month DAPT
group (67 patients, 88 lesions) and a 12-month conventional DAPT group (61 patients, 81 lesions). Coronary angiographic followup
and clinical followupwere conducted atmore than 8months and at 12months after ZES implantation, respectively.Minor andmajor
bleeding events, stent thrombosis (ST), and major adverse cardiac events (MACE) (death, myocardial infarction, cerebrovascular
accident, target lesion revascularization, and target vessel revascularization) were evaluated. There were no statistically significant
differences in the incidences of ST and MACE between the two groups. The incidence of bleeding events was significantly lower in
the 3-month group than in the 12-month group (1.5% versus 11.5%, 𝑃 < 0.05). DAPT can be safely discontinued at 3 months after
ZES implantation, which reduces bleeding risk.
1. Introduction
DESs have reduced the incidences of in-stent restenosis
and target lesion revascularization (TLR) compared to those
with bare-metal stents (BMS). The 2007 Focused Update
of ACC/AHA/SCAI Guidelines for Percutaneous Coronary
Intervention (PCI) recommends dual antiplatelet therapy
(DAPT) with aspirin and a thienopyridine drug ideally up
to 12 months after DES implantation [1]. This long DAPT
after DES implantation is associated with an increased risk of
bleeding, for example, gastrointestinal bleeding and intracra-
nial hemorrhage [2–11]. Major bleeding may deteriorate the
quality of life of patients by deferring an endoscopic, dental,
or surgical procedure [12].
Little evidence about the optimal duration of DAPT
is available [4, 7]. Recent studies demonstrated that the
duration of DAPT might be shortening when an endeavor
zotarolimus-eluting stent (ZES, Medtronic Inc., Santa Rosa,
CA) is used. ZES is a second-generation cobalt-alloy DES
that has a highly biocompatible polymer permitting rapid
release of the antiproliferative substance zotarolimus. ZES
has been reported (1) to accelerate arterial healing com-
pared with other DESs in animals [13–15], (2) to be safe
in humans for 5 years [16], and (3) to have a low risk
for development of myocardial infarction (MI) and late
stent thrombosis (ST) compared with a paclitaxel-eluting
stent [17]. The aim of the present study was to deter-
mine whether DAPT can be safely switched to aspirin
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monotherapy as early as 3 months after ZES implan-
tation.
2. Materials and Methods
2.1. Study Population. We retrospectively studied 168 consec-
utive patients (239 lesions) with significant coronary stenosis
who underwent PCI with ZES at our hospital from June 2009
through March 2010. As ZES has good product profiles for a
short duration of DAPT and the description of ZESmentions
discontinuing DAPT at 3 months, we had switched from
DAPT to aspirin monotherapy at 3 months in patients who
could have accepted our informed consent.
In this study, patients were eligible for participation based
on the following inclusion criteria (1) clinically significant
coronary stenosis (diameter stenosis>70%or diameter steno-
sis>50%with objective evidence ofmyocardial ischemia), (2)
de novo coronary restenotic lesions, and (3) restenotic coro-
nary lesions. Exclusion criteria were (1) acute MI, (2) receiv-
ing antiplatelet agents other than aspirin and clopidogrel, (3)
receiving antithrombotic drugs (e.g., warfarin), (4) expected
survival of less than 1 year, (5)major bleedingwithin 3months
of PCI, (6) previously having undergone PCI with other
DESs, (7) bifurcation lesions requiring side branch stenting,
and (8) not switching from DAPT to aspirin monotherapy at
3 months or 12 months after ZES implantation. There were
168 patients who met the inclusion criteria, and 40 patients
had one of the exclusion criteria. Consequently, there were 67
patients who switched from DAPT to aspirin monotherapy
at 3 months and they were assigned to a 3-month DAPT
group. 61 patients, who conventionally continued DAPT for
12 months, were assigned to a control group (12-month
DAPT group). Figure 1 shows the enrollment of patients.The
protocol of the present study was approved by the ethics
committee at our hospital, and all patients provided written
informed consent.
2.2. PCI Procedure and Protocol of Antiplatelet Therapy.
If patients had not received oral antiplatelet agents, load-
ing doses of aspirin (100–200mg/day) and clopidogrel
(300mg/day) were given before PCI. Routine anticoagu-
lation therapy was performed during PCI. All procedures
were performed with the standard interventional techniques.
Predilation, stent implantation, postdilation, and intravas-
cular ultrasound were conducted at the discretion of the
operator. Aspirin (100mg/day) was given indefinitely after
ZES implantation. Clopidogrel (75mg/day) was discontinued
at 3 months after ZES implantation and switched to aspirin
monotherapy in patients who had accepted our informed
consent (3-month DAPT group), while DAPT was continued
for 12 months after ZES in other patients as usual (12-month
DAPT group).
2.3. Followup and Endpoints. Patient’s information was col-
lected from medical records and by phone contact when
the patient did not visit the hospital. Clinical followup was
performed by medical examination on an outpatient basis or
by phone at 1, 3, 8, and 12 months after ZES implantation.
Drug adherence and bleeding events were assessed at the
time of followup. Coronary angiographic followup was per-
formed whenever possible in patients at more than 8 months
after ZES implantation. Quantitative coronary angiogra-
phy (QCA) was conducted based on coronary angiograms
obtained before, immediately after, and at 8 months after
ZES implantation. Reference vessel diameter (RVD),minimal
lumen diameter (MLD), and lesion length were measured
by experienced angiographers (N.M., K.H., A.W., and T.W.).
Acute gain was calculated as the difference between post- and
preprocedural MLDs. Late loss was defined as the difference
between postprocedural and late MLDs. Stent restenosis was
defined as a percent diameter stenosis (%DS) value of ≥ 50%.
The primary endpoints were minor and major bleeding
events and ST. Early (≤30 days) and late (31–365 days),
STs (“Definite,” “Probable,” or “Possible”) were assessed on
the basis of Academic Research Consortium (ARC) criteria
[18]. Definitions of bleeding events were based on the PCI
CURE study [19]: major bleeding was defined as bleeding
that was significantly disabling, intraocular, or requiring at
least 2 units of blood. Major bleeding was subclassified as life
threatening if it was fatal, if it led to a decrease in hemoglobin
concentration of 50 g/L, if it caused significant hypotension
requiring intravenous inotropes or surgical intervention, if
it resulted in symptomatic intracranial hemorrhage, or if
it necessitated transfusion of 4 or more units of blood;
and minor bleeding was defined as bleeding that led to
interruption of study medication.
The secondary endpoints were major adverse cardiac
events (MACE) (cardiac death, MI, cerebrovascular accident
(CVA), TLR, and target vessel revascularization (TVR)).
MI was defined as the presence of clinical signs involving
increases in creatine kinaseMB and troponin T that exceeded
the reference values. Periprocedural MI was excluded from
this study. TLR andTVRwere defined as repeat PCI or bypass
graft surgery for the target lesion and vessel, respectively.
2.4. Statistical Analysis. Continuous variables were expressed
as mean ± standard deviation. The means between the
two groups were tested by Student’s 𝑡-test or the Mann-
Whitney 𝑈 test. Discontinuous variables and nominal vari-
ables were expressed as frequencies and percentages. Differ-
ences between the two groups were tested by the 𝜒2 testor
Fisher’s test. A value of 𝑃 < 0.05 was considered statistically
significant. JMP7 (SAS Institute, Cary, NC) was used for the
analysis.
3. Results
3.1. Baseline Characteristics of Patients. Patients assessed
were 168 consecutive patients (239 lesions) who underwent
PCI with ZES for coronary artery disease (CAD) at our
hospital from June 2009 through March 2010. Among them,
39 patients (69 lesions) were excluded because they took
warfarin and an antiplatelet agent other than aspirin and
clopidogrel, had previously undergone implantation of other
DESs, or had bifurcation lesions requiring side branch stent-
ing. In addition, 1 patient (1 lesion) stopped taking clopidogrel
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168 patients recruited
∙ 20 taking other antiplatelet drugs or warfarin
∙ 18 with previous implantation of other DESs
∙ 0 with bleedings within 3 months after stent
implantation
40 exclusions
67 patients
(3-month DAPT group)
61 patients
(12-month DAPT group)
∙ 1 with a bifurcation lesion requiring
side branch stenting
61 conventionally discontinuing
clopidogrel at 12 months
(control group)
∙ 1 discontinuing clopidogrel at 5 months
Figure 1: Enrollment of patients. DAPT: dual antiplatelet therapy.
Table 1: Baseline characteristics of patients in the 3- and 12-month
DAPT groups.
3-month
DAPT
𝑛 = 67
12-month
DAPT
𝑛 = 61
𝑃 value
Male gender, n (%) 43 (64.8) 31 (51.8) 0.05
Age, yrs 70.3 ± 9.8 70.8 ± 9.2 NS
Stable angina, n (%) 52 (78.2) 48 (78.7) NS
Acute coronary
syndrome, n (%) 15 (21.8) 14 (23.0) NS
Prior myocardial
infarction, n (%) 10 (14.8) 8 (13.1) NS
Prior PCI, n (%) 18 (27.3) 18 (29.5) NS
Prior CABG, n (%) 3 (4.5) 1 (1.6) NS
Heart failure, n (%) 7 (10.2) 8 (13.1) NS
Diabetes mellitus, n (%) 33 (49.2) 30 (49.2) NS
Hypertension, n (%) 59 (87.5) 49 (80.3) NS
Dyslipidemia, n (%) 50 (74.6) 46 (75.4) NS
Current smoker, n (%) 34 (50.8) 21 (34.3) 0.02
Cr: >2.0mg/dL, n (%) 5 (6.8) 7 (11.5) NS
DAPT: dual antiplatelet therapy; PCI: percutaneous coronary intervention;
Cr: creatinine; NS: not significant.
at 5months after ZES implantation. Consequently, 67 patients
(88 lesions) and 61 patients (81 lesions) were enrolled in
the 3- and 12-month DAPT groups, respectively (Figure 1).
Baseline characteristics of patients are shown in Table 1.
Rations of males (64.8% versus 51.8%, 𝑃 = 0.05) and smokers
(50.8% versus 34.3%, 𝑃 = 0.02) were higher in the 3-month
DAPT group than in the 12-month DAPT group. However,
no statistically significant difference was found between the
two groups with respect to other baseline characteristics of
patients. Patients in the two groups had a relatively highmean
age of about 70 years and included high-risk patients for ST,
that is, patients with decreased renal function and patients
with decreased cardiac function caused by old MI.
3.2. Lesion Characteristics and Angiographic Outcomes.
Lesion characteristics and coronary angiographic outcomes
are shown in Table 2. At baseline, lesion length was signifi-
cantly shorter in the 3-month DAPT group than in the 12-
month DAPT group (13.3 ± 7.04mm versus 15.6 ± 5.82mm,
𝑃 = 0.02). However, there was no statistically significant
difference in the percentage of left main trunk (LMT) lesions
(4.9% versus 7.4%, 𝑃 = 0.31). At 8 months afterprocedure, no
statistically significant differences were found between the 3-
and 12-month DAPT groups in the following variables: TLR
(9.1% versus 9.9%, 𝑃 = 0.52), TVR (9.1% versus 9.9%, 𝑃 =
0.52), QCA [RVD (2.38 ± 0.53mm versus 2.64 ± 0.51mm,
𝑃 = 0.31), MLD (2.24 ± 0.58mm versus 2.16 ± 0.79mm, P
= 0.46), %DS (19.7 ± 17.3% versus 21.4 ± 20.2%, 𝑃 = 0.27),
and late lumen loss (0.45 ± 0.52mm versus 0.51 ± 0.47mm,
𝑃 = 0.51)].
3.3. Primary and Secondary Endpoints. All patients could
be followed up clinically (mean follow-up period: 411 ± 62
days). The incidences of bleeding events during the follow-
up period are shown in Figure 2. Major bleeding was not
observed in either group. The incidence of minor bleeding
events was significantly lower in the 3-month DAPT group
than in the 12-month DAPT group (1.5% versus 11.5%, 𝑃 =
0.02). In the 3-month DAPT group, one patient had upper
gastrointestinal bleeding at 6 months after ZES implantation.
In the 12-month DAPT group, nasal bleeding that required
hemostasis in the Department of Otorhinolaryngology was
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Table 2: Lesion characteristics and coronary angiographic out-
comes at baseline, immediately after and at 8 months after implan-
tation of the endeavor zotarolimus-eluting stent in the 3- and 12-
month DAPT groups.
3-month
DAPT
(88 lesions)
12-month
DAPT
(81 lesions)
𝑃-value
Baseline
RCA, n (%) 36 (40.5) 28 (34.6)
LAD, n (%) 33 (37.5) 29 (35.8) NS
LCX, n (%) 15 (17.1) 18 (22.2)
LMT, n (%) 4 (4.9) 6 (7.4) NS
AHA/ACC Type B1, n (%) 22 (24.7) 26 (32.0)
Type B2, n (%) 54 (61.6) 43 (53.0) NS
Type C, n (%) 5 (5.7) 3 (3.7)
De novo, n (%) 86 (97.7) 79 (97.5) NS
In-stent restenosis, n (%) 2 (2.3) 2 (2.5) NS
Bifurcation lesion, n (%) 6 (6.8) 7 (8.6) NS
Multivessel disease, n (%) 18 (20.5) 20 (24.7) NS
Lesion length, mm 13.3 ± 7.04 15.6 ± 5.82 0.02
RVD, mm 2.78 ± 0.52 2.74 ± 0.53 NS
MLD, mm 0.69 ± 0.43 0.71 ± 0.39 NS
%DS, % 73.9 ± 17.3 73.2 ± 14.9 NS
Immediately afterprocedure
Multiple stenting, n (%) 19 (21.5) 15 (18.5) NS
Number of stents per patient 1.7 ± 1.1 1.8 ± 0.7 NS
MLD, mm 2.39 ± 0.56 2.51 ± 0.61 NS
%DS, % 9.07 ± 7.56 7.94 ± 6.69 NS
8 months afterprocedure
RVD, mm 2.38 ± 0.53 2.64 ± 0.51 NS
MLD, mm 2.24 ± 0.58 2.16 ± 0.79 NS
%DS, % 19.7 ± 17.3 21.4 ± 20.2 NS
Late lumen loss, mm 0.45 ± 0.52 0.51 ± 0.47 NS
Binary restenosis, n (%) 8 (9.1) 9 (11.1) NS
RCA: right coronary artery; LAD: left coronary artery; LCX: left circumflex
artery; RVD: reference vessel diameter; MLD: minimal lumen diameter;
TLR: target lesion revascularization; TVR: target vessel revascularization;
LMT: left main trunk; DAPT: dual antiplatelet therapy; DS: diameter
stenosis; NS: not significant.
Table 3: Incidences of sent thrombosis in the 3- and 12-month
DAPT groups after implantation of the endeavor zotarolimus-
eluting stent.
3-month
DAPT
(88 lesions)
12-month
DAPT
(81 lesions)
𝑃-value
Stent thrombosis, 𝑛 (%) 0 (0) 1 (1.2) NS
0–30 days, 𝑛 (%) 0 (0) 0 (0) NS
31–365 days, 𝑛 (%) 0 (0) 1 (1.2) NS
DAPT: dual antiplatelet therapy; NS: not significant.
found in 4 patients (2, 4, 5, and 9 months after ZES implan-
tation, resp.), lower gastrointestinal bleeding was found in
Table 4: Incidences of major adverse cardiac events in the 3- and
12-month DAPT groups.
3-month
DAPT
(88 lesions)
12-month
DAPT
(81 lesions)
𝑃-value
MACE, n (%) 10 (11.4) 9 (11.1) NS
Death (all causes), n (%) 0 (0) 1 (1.2) NS
Cardiac death, n (%) 0 (0) 1 (1.2) NS
MI (all causes), n (%) 2 (2.3) 1 (1.2) NS
Q-MI, n (%) 1 (1.1) 1 (1.2) NS
non-Q-MI, n (%) 1 (1.1) 0 (0) NS
Cerebrovascular accident, n (%) 0 (0) 1 (1.2) NS
TLR, n (%) 8 (9.1) 8 (9.9) NS
TVR, n (%) 8 (9.1) 8 (9.9) NS
DAPT: dual antiplatelet therapy; MACE: major adverse cardiac events; MI:
myocardial infarction; TLR: target lesion revascularization; TVR: target
vessel revascularization; NS: not significant.
Major bleeding Minor bleeding
0%
1.5%
0%
11.5%
3-month DAPT group
12-month DAPT group
𝑃 = 0.02
𝑃 = NS
Figure 2: Incidences of bleeding events in the 3- and 12-month
DAPT groups. DAPT: dual antiplatelet therapy; NS: not significant.
2 patients (4 and 7 months after ZES implantation, resp.),
and upper gastrointestinal bleeding was found in one patient
(6 months after ZES implantation). The incidences of ST in
the two groups after ZES implantation are shown in Table 3.
Although the 12-month DAPT group included one patient
with ST, no significant difference was found between the two
groups (0% versus 1.2%, 𝑃 = 0.38).
The incidences of MACE are shown in Table 4. No
significant differences were found between the 3- and 12-
monthDAPTgroups in the following variables:MACE (11.4%
versus 11.1%, 𝑃 = 0.48); cardiac death (0% versus 1.2%, 𝑃 =
0.38), MI (all causes) (2.3% versus 1.2%, 𝑃 = 0.48), Q-MI
(1.1% versus 1.2%, 𝑃 = 0.64), non-Q-MI (1.1% versus 0%,
𝑃 = 0.41), TLR (9.1% versus 9.9%, 𝑃 = 0.52), and TVR (9.1%
versus 9.9%, 𝑃 = 0.52).
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4. Discussion
Our study demonstrated that switching fromDAPT to aspirin
monotherapy at 3 months after ZES implantation was not
associated with an increased incidence of ST or MACE but
was associated with a reduction in the incidence of minor
bleeding. To the best of our knowledge, the present study
is the first study to demonstrate the safety of switching
from DAPT to aspirin monotherapy 3 months after ZES
implantation in patients with CAD.
The optimal duration of DAPT after DES has not been
fully established. The PCI-CURE [19], CHARISMA [20],
CREDO [21], and other clinical studies have shown that ex-
tended oral administration of clopidogrel afterDES implanta-
tion can reduce the risk of cardiovascular complications, for
example, cardiac death and MI. Other clinical studies [4, 7,
22] have shown no obvious clinical benefits of DAPT lasting
for 6 months or more. The CHARISMA study, the only ran-
domized study among the above studies, did not demonstrate
the clinical benefits of continued DAPT for asymptomatic
patients. There has been no randomized prospective study
that has truly demonstrated clinical benefits of the long-term
continuation of DAPT.
DAPT can be a risk factor for bleeding events. In the
CHARISMA study, the incidence of major bleeding causing
hemodynamic disruption in the 2-year continued DAPT
group was 1.7% [20].What should be noted is the fact that the
incidence ofmajor bleeding is higher than the incidence of ST
thatmay develop during the same time span. Asian people are
considered to be at high risk for intracranial hemorrhage [23].
A prospective multicenter observational study in Japanese
patients undergoing continued DAPT has shown an annual
incidence of 0.6% for intracranial hemorrhage and an overall
annual incidence of 16.6% for bleeding events [24].Therefore,
DAPT is considered to be an independent risk factor for
bleeding events. On the other hand, 5-year followup after PCI
showed that 26% of patients underwent noncardiac surgery
[25]. In another study, 6.3%of patients underwent noncardiac
surgery requiring the discontinuation of DAPT within 1 year
after ZES implantation [17]. If we could switch DAPT to
aspirinmonotherapy early after DES implantation, the risk of
bleeding events could be lowered and the problems associated
with surgery could be lessened, resulting in improvement in
the quality of life of patients. Previous studies have provided
valuable evidence regarding the incidences of bleeding events
associatedwithDAPT, but there has been limited information
on the safety and clinical outcomes of early switching from
DAPT to aspirin monotherapy after DES implantation that
is required by cardiologists. A prospective study to assess
the safety of discontinuing clopidogrel in a short time span
after ZES implantation is ongoing [26, 27]. We believe that a
shorter duration ofDAPT after ZES should be associatedwith
better quality of life of patients undergoing PCI.
Among DESs, ZES has good product profiles for a short
duration of DAPT. ZES rapidly releases an antiprolifera-
tive drug to surrounding tissue, enhancing the coverage
of endothelial cells on it. A study by optical coherence
tomography (OCT) showed complete neointimal coverage
as early as 3 months after ZES implantation [28]. Another
study by OCT showed that ZES has few bare-stent struts and
little thrombosis compared to a sirolimus-eluting stent at 9
months after implantation [29]. ZES showed significantly less
acetylcholine-induced vasoconstriction than did a sirolimus-
eluting stent [15].These studies indicate high safety profiles of
ZES: acceleration of reendothelialization and preservation of
endothelial function. In the present study, therefore, we used
ZES as a DES with the greatest potential for shortening the
duration of DAPT for the reasons discussed above.
Early switching from DAPT to aspirin monotherapy
after DES implantation may increase the risk of ST. Hahn
et al. reported that discontinuation of DAPT at 3 month
after ZES implantation was not associated with an increased
incidence of ST [27]. None of the observational studies on
the relationship betweenDAPTduration and ST succeeded in
showing a relationship between late ST and DAPT duration.
In this study, we showed that DAPT for 3 months after
ZES implantation is not associated with risk of ST com-
pared with DAPT for 12 months. On the other hand, the
short duration of DAPT may increase the risk of in-stent
restenosis because platelets that have adhered to the stent
may release chemoattractants and proliferative factors to
enhance the migration and proliferation of vascular smooth
muscle cells. However, there was no difference in MLD,
late loss, and %DS between the two groups at 8 months
after implantation. There was also no difference in the
incidence of MACE between the two groups. Consequently,
our study has provided useful information for the short-
ening of the duration of DAPT in the real-world clinical
setting.
The present study has several limitations. First, the study
was retrospectively conducted at a single medical institution
and the study population was small. Second, the patients in
the 3-month DAPT group were not selected randomly, and
selection bias may exist in the preventive effect of DAPT
on cardiovascular events and in baseline characteristics of
patients. Third, the number of ST was very low in both
groups. Longer observation will be needed to evaluate the
incidence of ST on very late phase. Fourth, the study used
ZES only and is therefore not a controlled study using another
DES. Since the assessment of safety and efficacy may differ
depending on the type of DES, further study will be needed
to corroborate the clinical evidence obtained in the present
study.
5. Conclusion
The 3-month DAPT group was equivalent to the 12-month
DAPT group in clinical outcomes and overall incidence of
MACE. The incidence of bleeding events was significantly
lower in the 3-month DAPT group than in the 12-month
DAPT group. Therefore, the present study suggests that
DAPT can be safely discontinued at 3 months after ZES
implantation in patients with CAD.
Although there was no difference in the incidence of ST
between the two groups, the 12-month DAPT group had
longer lesion length. The short duration of DAPT therapy
may apply to longer stent length.
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